Antony, France

Evanghelos Bricas

This inventor holds 1 USPTO granted patent. Top assignee: Agence Nationale De Valorisation De La Recherche (Anvar). Active years: 1981.


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 1981

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Evanghelos Bricas: Innovator in Polypeptide Research

Introduction

Evanghelos Bricas is a notable inventor based in Antony, France. He has made significant contributions to the field of biochemistry, particularly in the development of novel polypeptides. His work focuses on compounds that exhibit thymic activity or antagonistic activity, which can have important implications in medical research and treatment.

Latest Patents

Evanghelos Bricas holds 1 patent for his invention titled "Novel polypeptides having thymic activity or an antagonistic activity." This patent involves innovative polypeptides and the processes for their synthesis. The compounds he has developed are characterized by specific sequences that may lead to advancements in therapeutic applications.

Career Highlights

Bricas is associated with the Agence Nationale De Valorisation De La Recherche (ANVAR), where he has been able to apply his expertise in a collaborative environment. His work at ANVAR has allowed him to contribute to the advancement of research and innovation in France.

Collaborations

Throughout his career, Evanghelos Bricas has collaborated with esteemed colleagues such as Jean-Francois Bach and Mireille Dardenne. These partnerships have enriched his research and expanded the impact of his inventions.

Conclusion

Evanghelos Bricas is a prominent figure in the field of polypeptide research, with a focus on innovative compounds that hold promise for future medical applications. His contributions through patents and collaborations highlight his commitment to advancing scientific knowledge and innovation.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…